Published in Bioorg Med Chem Lett on June 23, 2012
A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium. Lancet Infect Dis (2014) 2.18
Potent and selective inhibitors of CDPK1 from T. gondii and C. parvum based on a 5-aminopyrazole-4-carboxamide scaffold. ACS Med Chem Lett (2014) 1.13
The gatekeeper residue and beyond: homologous calcium-dependent protein kinases as drug development targets for veterinarian Apicomplexa parasites. Parasitology (2014) 1.01
Protein kinases of Toxoplasma gondii: functions and drug targets. Parasitol Res (2013) 0.93
SAR Studies of 5-Aminopyrazole-4-carboxamide Analogues as Potent and Selective Inhibitors of Toxoplasma gondii CDPK1. ACS Med Chem Lett (2015) 0.92
In Vitro and In Vivo Effects of the Bumped Kinase Inhibitor 1294 in the Related Cyst-Forming Apicomplexans Toxoplasma gondii and Neospora caninum. Antimicrob Agents Chemother (2015) 0.85
A Proposed Target Product Profile and Developmental Cascade for New Cryptosporidiosis Treatments. PLoS Negl Trop Dis (2015) 0.83
Optimization of an imidazopyridazine series of inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1). J Med Chem (2014) 0.80
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds. PLoS One (2016) 0.80
A Novel Calcium-Dependent Kinase Inhibitor, Bumped Kinase Inhibitor 1517, Cures Cryptosporidiosis in Immunosuppressed Mice. J Infect Dis (2016) 0.79
Triazole-based compound as a candidate to develop novel medicines to treat toxoplasmosis. Antimicrob Agents Chemother (2014) 0.79
Preassembled Single-Stranded RNA-Argonaute Complexes: A Novel Method to Silence Genes in Cryptosporidium. J Infect Dis (2015) 0.78
CDPKs of Cryptosporidium parvum--stage-specific expression in vitro. Parasitol Res (2014) 0.77
Review of Experimental Compounds Demonstrating Anti-Toxoplasma Activity. Antimicrob Agents Chemother (2016) 0.75
Identification and Validation of Small-Gatekeeper Kinases as Drug Targets in Giardia lamblia. PLoS Negl Trop Dis (2016) 0.75
Drugs in development for toxoplasmosis: advances, challenges, and current status. Drug Des Devel Ther (2017) 0.75
Extended-spectrum antiprotozoal bumped kinase inhibitors: A review. Exp Parasitol (2017) 0.75
Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science (2005) 5.53
Toxoplasma gondii infection in the United States: seroprevalence and risk factors. Am J Epidemiol (2001) 4.12
A second-site suppressor strategy for chemical genetic analysis of diverse protein kinases. Nat Methods (2005) 2.47
Calcium-dependent signaling and kinases in apicomplexan parasites. Cell Host Microbe (2009) 2.46
Toxoplasma gondii calcium-dependent protein kinase 1 is a target for selective kinase inhibitors. Nat Struct Mol Biol (2010) 2.34
Toxoplasma gondii attachment to host cells is regulated by a calmodulin-like domain protein kinase. J Biol Chem (2001) 1.93
Structures of apicomplexan calcium-dependent protein kinases reveal mechanism of activation by calcium. Nat Struct Mol Biol (2010) 1.91
Comparative genomic and phylogenetic analyses of calcium ATPases and calcium-regulated proteins in the apicomplexa. Mol Biol Evol (2006) 1.83
Discovery of Potent and Selective Inhibitors of Calcium-Dependent Protein Kinase 1 (CDPK1) from C. parvum and T. gondii. ACS Med Chem Lett (2010) 1.82
Development of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) inhibitors with potent anti-toxoplasma activity. J Med Chem (2012) 1.56
Use of the kinase inhibitor analog 1NM-PP1 reveals a role for Toxoplasma gondii CDPK1 in the invasion step. Eukaryot Cell (2010) 1.54
Surveillance for waterborne-disease outbreaks associated with drinking water--United States, 2001-2002. MMWR Surveill Summ (2004) 1.50
Protein kinases as targets for antimalarial intervention: Kinomics, structure-based design, transmission-blockade, and targeting host cell enzymes. Biochim Biophys Acta (2005) 1.46
Multiple determinants for selective inhibition of apicomplexan calcium-dependent protein kinase CDPK1. J Med Chem (2012) 1.35
Optimal description of a protein structure in terms of multiple groups undergoing TLS motion. Acta Crystallogr D Biol Crystallogr (2006) 14.21
Retention in care: a challenge to survival with HIV infection. Clin Infect Dis (2007) 10.66
A high-resolution, nucleosome position map of C. elegans reveals a lack of universal sequence-dictated positioning. Genome Res (2008) 7.77
The genome sequence of Trypanosoma cruzi, etiologic agent of Chagas disease. Science (2005) 7.61
The C elegans hunchback homolog, hbl-1, controls temporal patterning and is a probable microRNA target. Dev Cell (2003) 6.74
Chemical genetics of Plasmodium falciparum. Nature (2010) 5.52
Determinants of nucleosome organization in primary human cells. Nature (2011) 5.50
Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS (2005) 5.08
Ubiquitous heterogeneity and asymmetry of the chromatin environment at regulatory elements. Genome Res (2012) 3.61
Current consensus guidelines for treatment of neurocysticercosis. Clin Microbiol Rev (2002) 3.37
Patients referred to an urban HIV clinic frequently fail to establish care: factors predicting failure. AIDS Care (2005) 2.64
Genomic-scale prioritization of drug targets: the TDR Targets database. Nat Rev Drug Discov (2008) 2.58
Heterologous expression of proteins from Plasmodium falciparum: results from 1000 genes. Mol Biochem Parasitol (2006) 2.45
The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis (2005) 2.43
Toxoplasma gondii calcium-dependent protein kinase 1 is a target for selective kinase inhibitors. Nat Struct Mol Biol (2010) 2.34
Factors associated with the use of highly active antiretroviral therapy in patients newly entering care in an urban clinic. J Acquir Immune Defic Syndr (2003) 2.33
Structure of an archaeal virus capsid protein reveals a common ancestry to eukaryotic and bacterial viruses. Proc Natl Acad Sci U S A (2005) 2.26
Neurocysticercosis: A natural human model of epileptogenesis. Epilepsia (2014) 2.11
New concepts in the diagnosis and management of neurocysticercosis (Taenia solium). Am J Trop Med Hyg (2005) 2.10
An updated review on Cryptosporidium and Giardia. Gastroenterol Clin North Am (2006) 2.05
Neuroendoscopic diagnosis of central nervous system histoplasmosis with basilar arachnoiditis. World Neurosurg (2011) 2.05
Widespread variation in transcript abundance within and across developmental stages of Trypanosoma brucei. BMC Genomics (2009) 2.00
Therapeutic intervention based on protein prenylation and associated modifications. Nat Chem Biol (2006) 1.96
Neurocysticercosis: neglected but not forgotten. PLoS Negl Trop Dis (2012) 1.95
Gene conversion: a mechanism for generation of heterogeneity in the tprK gene of Treponema pallidum during infection. Mol Microbiol (2004) 1.94
Protein kinases as drug targets in trypanosomes and Leishmania. Biochim Biophys Acta (2005) 1.87
A molecular viewer for the analysis of TLS rigid-body motion in macromolecules. Acta Crystallogr D Biol Crystallogr (2005) 1.82
Discovery of Potent and Selective Inhibitors of Calcium-Dependent Protein Kinase 1 (CDPK1) from C. parvum and T. gondii. ACS Med Chem Lett (2010) 1.82
Protein farnesyltransferase inhibitors exhibit potent antimalarial activity. J Med Chem (2005) 1.81
Sequence determinants of a specific inactive protein kinase conformation. Chem Biol (2013) 1.78
Growing problem of multidrug-resistant enteric pathogens in Africa. Emerg Infect Dis (2007) 1.78
Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study. AIDS (2004) 1.74
Rational modification of a candidate cancer drug for use against Chagas disease. J Med Chem (2009) 1.73
Administration of protein-conjugate pneumococcal vaccine to patients who have invasive disease after splenectomy despite their having received 23-valent pneumococcal polysaccharide vaccine. J Infect Dis (2005) 1.72
A specific inhibitor of PfCDPK4 blocks malaria transmission: chemical-genetic validation. J Infect Dis (2013) 1.71
Cooperative hydrogen bond interactions in the streptavidin-biotin system. Protein Sci (2006) 1.67
Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection. Cochrane Database Syst Rev (2016) 1.66
Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations. Cancer Res (2009) 1.64
Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses. Curr Opin Struct Biol (2010) 1.62
Protein farnesyl and N-myristoyl transferases: piggy-back medicinal chemistry targets for the development of antitrypanosomatid and antimalarial therapeutics. Mol Biochem Parasitol (2003) 1.61
The protein farnesyltransferase inhibitor Tipifarnib as a new lead for the development of drugs against Chagas disease. J Med Chem (2005) 1.60
Second generation tetrahydroquinoline-based protein farnesyltransferase inhibitors as antimalarials. J Med Chem (2007) 1.60
Nucleotide sequence and organization of the multiresistance plasmid pSCFS1 from Staphylococcus sciuri. J Antimicrob Chemother (2004) 1.60
Development of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) inhibitors with potent anti-toxoplasma activity. J Med Chem (2012) 1.56
A positive enzyme-linked immunoelectrotransfer blot assay result for a patient without evidence of cysticercosis. Clin Infect Dis (2002) 1.49
High-resolution structural and thermodynamic analysis of extreme stabilization of human procarboxypeptidase by computational protein design. J Mol Biol (2006) 1.49
Protection against syphilis correlates with specificity of antibodies to the variable regions of Treponema pallidum repeat protein K. Infect Immun (2003) 1.49
Divergent allosteric control of the IRE1α endoribonuclease using kinase inhibitors. Nat Chem Biol (2012) 1.46
Efficacy, pharmacokinetics, and metabolism of tetrahydroquinoline inhibitors of Plasmodium falciparum protein farnesyltransferase. Antimicrob Agents Chemother (2007) 1.43
Segregation of B and T cell epitopes of Treponema pallidum repeat protein K to variable and conserved regions during experimental syphilis infection. J Immunol (2002) 1.43
Contemporary neurosurgical approaches to neurocysticercosis. Am J Trop Med Hyg (2009) 1.41
Molecular differentiation of Treponema pallidum subspecies. J Clin Microbiol (2006) 1.39
Identification of attractive drug targets in neglected-disease pathogens using an in silico approach. PLoS Negl Trop Dis (2010) 1.39
Compartmentation prevents a lethal turbo-explosion of glycolysis in trypanosomes. Proc Natl Acad Sci U S A (2008) 1.37
High-throughput protein production and purification at the Seattle Structural Genomics Center for Infectious Disease. Acta Crystallogr Sect F Struct Biol Cryst Commun (2011) 1.37
Characterization of protein kinase CK2 from Trypanosoma brucei. Mol Biochem Parasitol (2006) 1.37
Selective inhibitors of methionyl-tRNA synthetase have potent activity against Trypanosoma brucei Infection in Mice. Antimicrob Agents Chemother (2011) 1.37
Thematic review series: lipid posttranslational modifications. Fighting parasitic disease by blocking protein farnesylation. J Lipid Res (2005) 1.36
Missense mutations in the regulatory domain of PKC gamma: a new mechanism for dominant nonepisodic cerebellar ataxia. Am J Hum Genet (2003) 1.36
Multiple determinants for selective inhibition of apicomplexan calcium-dependent protein kinase CDPK1. J Med Chem (2012) 1.35
Urea-based inhibitors of Trypanosoma brucei methionyl-tRNA synthetase: selectivity and in vivo characterization. J Med Chem (2012) 1.35
Recognition of the iso-ADP-ribose moiety in poly(ADP-ribose) by WWE domains suggests a general mechanism for poly(ADP-ribosyl)ation-dependent ubiquitination. Genes Dev (2012) 1.33
Self-medication with antibiotics for the treatment of menstrual symptoms in Southwest Nigeria: a cross-sectional study. BMC Public Health (2010) 1.33
The NOG1 GTP-binding protein is required for biogenesis of the 60 S ribosomal subunit. J Biol Chem (2003) 1.33
CTX-M-15 extended-spectrum (beta)-lactamase from Nigerian Klebsiella pneumoniae. J Antimicrob Chemother (2005) 1.32